This Article Full Text Full Text (PDF) All Versions of this Article: 117/10/1255    most recent CIRCULATIONAHA.107.744466v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Watanabe, H. Articles by Aizawa, Y. PubMed PubMed Citation Articles by Watanabe, H. Articles by Aizawa, Y. Related Collections Arrhythmias, clinical electrophysiology, drugs Epidemiology Glucose intolerance Related Article

(Circulation. 2008;117:1255-1260.)
© 2008 American Heart Association, Inc.

Arrhythmia/Electrophysiology

Metabolic Syndrome and Risk of Development of Atrial Fibrillation

The Niigata Preventive Medicine Study

Hiroshi Watanabe, MD, PhD; Naohito Tanabe, MD, PhD; Toru Watanabe, MD, PhD; Dawood Darbar, MD, PhD; Dan M. Roden, MD; Shigeru Sasaki, MD, PhD; Yoshifusa Aizawa, MD, PhD

From the Division of Cardiology (H.W., Y.A.) and Department of Public Health (N.T.), Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; Niigata Association for Comprehensive Health Promotion and Research, Niigata, Japan (T.W., S.S.); and Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn (H.W., D.D., D.M.R.).

Correspondence to Hiroshi Watanabe, MD, PhD, Department of Medicine, Vanderbilt University School of Medicine, 2215B Garland Ave, Room 1275, Nashville, TN 37232–0575. E-mail hiroshi7{at}med.niigata-u.ac.jp

Received October 29, 2007; accepted December 11, 2007.

Background— The metabolic syndrome consists of a cluster of atherosclerotic risk factors, many of which also have been implicated in the genesis of atrial fibrillation (AF). However, the precise role of the metabolic syndrome in the development of AF is unknown.

Methods and Results— This prospective, community-based, observational cohort study was based on an annual health check-up program in Japan. We studied 28 449 participants without baseline AF. We used 2 different criteria for the metabolic syndrome—the guidelines of the National Cholesterol Education Program Third Adult Treatment Panel (NCEP-ATP III) and those of the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI)—to study the risk of development of new-onset AF. The metabolic syndrome was present in 3716 subjects (13%) and 4544 subjects (16%) using the NCEP-ATP III and AHA/NHLBI definitions, respectively. During a mean follow-up of 4.5 years, AF developed in 265 subjects (105 women). Among the metabolic syndrome components, obesity (age- and sex-adjusted hazard ratio [HR], 1.64), elevated blood pressure (HR, 1.69), low high-density lipoprotein cholesterol (HR, 1.52), and impaired insulin tolerance (HR, 1.44 [NCEP-ATP III] and 1.35 [AHA/NHLBI]) showed an increased risk for AF. The association between the metabolic syndrome and AF remained significant in subjects without treated hypertension or diabetes by the NCEP-ATP III definition (HR, 1.78) but not by the AHA/NHLBI definition (HR, 1.28).

Conclusions— The metabolic syndrome was associated with increased risk of AF. The metabolic derangements of the syndrome may be important in the pathogenesis of AF.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 117: 1247. [Full Text]